{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:53:27Z","timestamp":1786982007340,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s11523-023-00985-3","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T11:58:48Z","timestamp":1692359928000},"page":"767-776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich"],"prefix":"10.1007","volume":"18","author":[{"given":"Danmei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Boukovala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp A.","family":"Greif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Ziemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Roessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Goni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Renz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan G.","family":"D\u2019Haese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Seidensticker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Niyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Ormanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kumbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Mock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rudelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Klauschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Mayerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Boeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5310-3754","authenticated-orcid":false,"given":"C. Benedikt","family":"Westphalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"985_CR1","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","volume":"76","author":"L Izquierdo-Sanchez","year":"2022","unstructured":"Izquierdo-Sanchez L, Lamarca A, la Casta A, Buettner S, Utpatel K, Kl\u00fcmpen HJ, et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022;76:1109\u201321.","journal-title":"J Hepatol"},{"issue":"10272","key":"985_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344.","journal-title":"Lancet"},{"issue":"9","key":"985_CR3","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41416-022-01932-1","volume":"127","author":"A Tomczak","year":"2022","unstructured":"Tomczak A, Springfeld C, Dill MT, Chang DH, Kazdal D, Wagner U, et al. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice. Br J Cancer. 2022;127(9):1701\u20138.","journal-title":"Br J Cancer"},{"issue":"24","key":"985_CR4","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1200\/JCO.21.02576","volume":"40","author":"AJ Scott","year":"2022","unstructured":"Scott AJ, Sharman R, Shroff RT. Precision medicine in biliary tract cancer. J Clin Oncol. 2022;40(24):2716\u201334.","journal-title":"J Clin Oncol"},{"issue":"11","key":"985_CR5","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7(11):1669\u201377.","journal-title":"JAMA Oncol"},{"key":"985_CR6","unstructured":"Pemazyre | European Medicines Agency [Internet]. [cited 2022 Oct 19]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pemazyre."},{"issue":"5","key":"985_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671\u201384.","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"985_CR8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1200\/JCO.2020.38.15_suppl.108","volume":"38","author":"L Goyal","year":"2020","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. FOENIX-CCA2: a phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements. J Clin Oncol. 2020;38(15_suppl):108.","journal-title":"J Clin Oncol"},{"key":"985_CR9","unstructured":"FDA grants accelerated approval to futibatinib for cholangiocarcinoma | FDA [Internet]. [cited 2022 Oct 31]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-futibatinib-cholangiocarcinoma."},{"issue":"3","key":"985_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228\u201339.","journal-title":"N Engl J Med"},{"key":"985_CR11","unstructured":"Lytgobi: Pending EC decision | European Medicines Agency [Internet]. [cited 2023 Jul 8]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/lytgobi."},{"issue":"5","key":"985_CR12","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/ajcp\/aqz199","volume":"153","author":"JY Ju","year":"2020","unstructured":"Ju JY, Dibbern ME, Mahadevan MS, Fan J, Kunk PR, Stelow EB. Mismatch repair protein deficiency\/microsatellite instability is rare in cholangiocarcinomas and associated with distinctive morphologies. Am J Clin Pathol. 2020;153(5):598\u2013604.","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"985_CR13","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s12328-021-01458-8","volume":"14","author":"K Toshida","year":"2021","unstructured":"Toshida K, Itoh S, Yoshizumi T, Shimagaki T, Wang H, Kurihara T, et al. Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report. Clin J Gastroenterol. 2021;14(5):1459\u201363.","journal-title":"Clin J Gastroenterol"},{"issue":"26","key":"985_CR14","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"issue":"9","key":"985_CR15","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","volume":"22","author":"M Javle","year":"2021","unstructured":"Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021;22(9):1290\u2013300.","journal-title":"Lancet Oncol"},{"issue":"3_suppl","key":"985_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1200\/JCO.2021.39.3_suppl.320","volume":"39","author":"JJ Harding","year":"2021","unstructured":"Harding JJ, Cleary JM, Quinn DI, Bra\u00f1a I, Moreno V, Borad MJ, et al. Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT \u2018basket\u2019 trial. J Clin Oncol. 2021;39(3_suppl):320.","journal-title":"J Clin Oncol"},{"issue":"9","key":"985_CR17","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","volume":"21","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Lassen U, \u00c9lez E, Italiano A, Curigliano G, Javle M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234\u201343.","journal-title":"Lancet Oncol"},{"key":"985_CR18","unstructured":"FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation | FDA [Internet]. [cited 2022 Oct 31]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid."},{"issue":"7","key":"985_CR19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","volume":"24","author":"JJ Harding","year":"2023","unstructured":"Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24(7):772\u201382.","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"985_CR20","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","volume":"40","author":"A Ohba","year":"2022","unstructured":"Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial). J Clin Oncol. 2022;40(16_suppl):4006.","journal-title":"J Clin Oncol"},{"issue":"11","key":"985_CR21","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491\u2013505.","journal-title":"Ann Oncol"},{"issue":"2","key":"985_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2022","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;34(2):127\u201340.","journal-title":"Ann Oncol"},{"key":"985_CR23","doi-asserted-by":"crossref","unstructured":"Heinrich K, Miller-Phillips L, Ziemann F, Hasselmann K, R\u00fchlmann K, Flach M, et al. Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board. J Cancer Res Clin Oncol. 2022:1\u201311.","DOI":"10.1007\/s00432-022-04165-0"},{"issue":"8","key":"985_CR24","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-21-2384","volume":"28","author":"H Verdaguer","year":"2022","unstructured":"Verdaguer H, Saur\u00ed T, Acosta DA, Guardiola M, Sierra A, Hernando J, et al. ESMO scale for clinical actionability of molecular targets driving targeted treatment in patients with cholangiocarcinoma. Clin Cancer Res. 2022;28(8):1662\u201371.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"985_CR25","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.annonc.2021.04.012","volume":"32","author":"TS Bekaii-Saab","year":"2021","unstructured":"Bekaii-Saab TS, Bridgewater J, Normanno N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol. 2021;32(9):1111\u201326.","journal-title":"Ann Oncol"},{"issue":"5","key":"985_CR26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.21037\/jgo.2016.09.01","volume":"7","author":"A Jain","year":"2016","unstructured":"Jain A, Javle M. Molecular profiling of biliary tract cancer: a target rich disease. J Gastrointest Oncol. 2016;7(5):797\u2013803.","journal-title":"J Gastrointest Oncol."},{"issue":"17","key":"985_CR27","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","volume":"24","author":"MA Lowery","year":"2018","unstructured":"Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154\u201361.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"985_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","volume":"11","author":"IM Silverman","year":"2021","unstructured":"Silverman IM, Hollebecque A, Friboulet L, Owens S, Newton RC, Zhen H, et al. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov. 2021;11(2):326\u201339.","journal-title":"Cancer Discov"},{"key":"985_CR29","first-page":"PO.20.00495","volume":"5","author":"KL Larson","year":"2021","unstructured":"Larson KL, Huang B, Weiss HL, Hull P, Westgate PM, Miller RW, et al. Clinical outcomes of Molecular Tumor Boards: a systematic review. JCO Precis Oncol. 2021;5:PO.20.00495.","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"985_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.trecan.2017.12.004","volume":"4","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Kurzrock R. Challenging standard-of-care paradigms in the precision oncology era. Trends Cancer. 2018;4(2):101\u20139.","journal-title":"Trends Cancer."},{"issue":"5","key":"985_CR31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/annonc\/mdz088","volume":"30","author":"IF Tannock","year":"2019","unstructured":"Tannock IF, Hickman JA. Molecular screening to select therapy for advanced cancer? Ann Oncol. 2019;30(5):661\u20133.","journal-title":"Ann Oncol"},{"key":"985_CR32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1136\/esmoopen-2019-000583","volume":"4","author":"A Mock","year":"2019","unstructured":"Mock A, Heilig CE, Kreutzfeldt S, Huebschmann D, Heining C, Schr\u00f6ck E, et al. Community-driven development of a modified progression-free survival ratio for precision oncology. ESMO Open. 2019;4:583.","journal-title":"ESMO Open."},{"key":"985_CR33","unstructured":"There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. | Clinical Cancer Research | American Association for Cancer Research [Internet]. [cited 2023 Apr 23]. Available from: https:\/\/aacrjournals.org\/clincancerres\/article\/4\/5\/1079\/7593\/There-are-no-bad-anticancer-agents-only-bad."},{"issue":"9","key":"985_CR34","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.trecan.2020.05.008","volume":"6","author":"C Luchini","year":"2020","unstructured":"Luchini C, Lawlor RT, Milella M, Scarpa A. Molecular tumor boards in clinical practice. Trends Cancer. 2020;6(9):738\u201344.","journal-title":"Trends Cancer."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00985-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-023-00985-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00985-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T05:18:12Z","timestamp":1695446292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-023-00985-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["985"],"URL":"https:\/\/doi.org\/10.1007\/s11523-023-00985-3","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"13 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DZ: travel finance and speaker\u2019s honoraria from AMGEN, AstraZeneca, Roche; KD: travel finance and speaker\u2019s honoraria from AMGEN, AstraZeneca, Servier, GSK; SB: speaker\u2019s honorarium or advisory boards for AstraZeneca, BMS, Incyte, Janssen-Cilag, MSD, Servier; research funding: Celgene; PG:\u00a0advisory board AstraZeneca;\u00a0DR: consulting fees from Bayer and Ipsen and lecture fee from Ipsen. CBW: honoraria from Amgen, Bayer, BMS, Chugai, Celgene, Falk, GSK, MSD, Merck, Janssen, Ipsen, Roche, Servier, SIRTeX, and Taiho; served on advisory boards for Bayer, BMS, Celgene, Janssen, MSD, Servier, Shire\/Baxalta, Rafael Pharmaceuticals, RedHill, and Roche; has received travel support from Bayer, Celgene, Janssen, RedHill, Roche, Servier, and Taiho and research grants (institutional) from Roche. CBW serves as an officer for the European Society of Medical Oncology, Deutsche Krebshilfe, and Arbeitsgemeinschaft internistische Onkologie, and is a member of the European Union Commission expert group: Mission Board for cancer. Authors BR, KH, LW, MB, MH, JD, MS, SC, KN, JA, AM, FK, JW, JM, FZ, GB, EG, WK, SO, JK, MB, AM, MR declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective chart review study involving human participants was in accordance with the principles of the Declaration of Helsinki and its later amendments. The study was approved by the local ethics committee of the Ludwig-Maximilians-University Munich (approval number: 21-0869).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate, consent to publish"}},{"value":"All data generated or analyzed during this study are included in this published article (and its supplementary information files).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by DZ, KD, and CBW. The first draft of the manuscript was written by DZ and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}